New horizons in therapeutic antibody discovery: Opportunities and challenges versus small-molecule therapeutics

Journal of Biomolecular Screening

Volumn 20, Issue 4, 2015, Pages 437-453

  Smith, Alison J ^a  

^a MEDIMMUNE   (United States)

Author keywords

ADC; antibody therapeutics; bispecifics; blood brain barrier; intracellular delivery; screening assays; small molecule; target landscape

Indexed keywords

ANTIBODY CONJUGATE; DRUG ANTIBODY; G PROTEIN COUPLED RECEPTOR; ION CHANNEL; ANTIBODY;

ALLOSTERISM; ANTIBODY ENGINEERING; ANTIBODY STRUCTURE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; HIGH THROUGHPUT SCREENING; HUMAN; INTRACELLULAR TRANSPORT; MEMBRANE PERMEABILITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; CHEMISTRY; DRUG DEVELOPMENT;

ANTIBODIES; DRUG DISCOVERY;

EID: 84925832282     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057114562544     Document Type: Review

References (187)

1. Wang Y., Hailey J., Williams D., et al. Inhibition of Insulin-Like Growth Factor-1 Receptor (IGF-1R) Signaling and Tumor Cell Growth by a Fully Human Neutralizing Anti-IGF1R Antibody. Mol. Cancer Ther. 2005 ; 4: 1214-1221
2. Jakobovits A., Amado R. G., Yang X., et al. From XenoMouse Technology to Panitumumab, the First Fully Human Antibody Product from Transgenic Mice. Nat. Biotechnol. 2007 ; 25: 1134-1143
3. Lonberg N.. Human Monoclonal Antibodies from Transgenic Mice. Handbook Exp. Pharmacol. 2008 ; 181: 69-97
4. Bradbury A. R. M., Sidhu S., Dubel S., et al. Beyond Natural Antibodies: The Power of In Vitro Display Technologies. Nat. Biotechnol. 2011 ; 29: 245-254
5. Griffiths A. D., Duncan A. R.. Strategies for Selection of Antibodies by Phage Display. Curr. Opin. Biotechnol. 1998 ; 9: 102-108
6. Sblattero D., Bradbury A.. Exploiting Recombination in Single Bacteria to Make Large Phage Antibody Libraries. Nat. Biotechnol. 2000 ; 18: 75-80
7. Hoogenboom H. R.. Selecting and Screening Recombinant Antibody Libraries. Nat. Biotechnol. 2005 ; 23: 1105-1116
8. Albrecht H., Radosevich J. A., Babich M.. Fundamentals of Antibody-Related Therapy and Diagnostics. Drugs Today (Barc). 2009 ; 45: 199-211
9. Dimitrov D. S., Marks J. D.. Therapeutic Antibodies: Current State and Future Trends: Is a Paradigm Change Coming Soon?. Methods Mol. Biol. 2009 ; 525: 1-27
10. Reichert J. M., Dhimolea E.. Foundation Review: The Future of Antibodies as Cancer Drugs. Drug Discov. Today. 2012 ; 17: 954-963
11. Reichert J. M.. Which Are the Antibodies to Watch in 2013?. mAbs. 2013 ; 5: 1-4
12. Reichert J. M.. Antibodies to Watch in 2014. mAbs. 2014 ; 6: 5-14
13. Fuh G., Wu P., Liang W.-C., et al. Structure-Function Studies of Two Synthetic Anti-Vascular Endothelial Growth Factor Fabs and Comparison with the Avastin™ Fab. J. Biol. Chem. 2006 ; 281: 6625-6631
14. Boder E. T., Midelfort K. S., Wittrup K. D.. Directed Evolution of Antibody Fragments with Monovalent Femtomolar Antigen-Binding Affinity. Proc. Natl. Acad. Sci. U. S. A. 2000 ; 97: 10701-10705
15. Niwa R., Natsume A., Uehara A., et al. IgG Subclass-Independent Improvement of Antibody-Dependent Cellular Cytotoxicity by Fucose Removal from Asn297-Linked Oligosaccharides. J. Immunol. Methods. 2005 ; 306: 151-160
16. Vincent K. J., Zurini M.. Current Strategies in Antibody Engineering: Fc Engineering and pH-Dependent Antigen Binding, Bispecific Antibodies and Antibody Drug Conjugates. Biotechnol. J. 2012 ; 7: 1444-1450
17. Shi S.. Biologics: An Update and Challenge of Their Pharmacokinetics. Curr. Drug. Metab. 2014 ; 15: 271-290
18. Kuo T. T., Aveson V. G.. Neonatal Fc Receptor and IgG-Based Therapeutics. mAbs. 2011 ; 3: 422-430
19. Igawa T., Ishii S., Tachibana T., et al. Antibody Recycling by Engineered pH-Dependent Antigen Binding Improves the Duration of Antigen Neutralization. Nat. Biotechnol. 2010 ; 28: 1203-1208
20. Gajadhar A. S., Bogdanovic E., Munoz D. M., et al. In Situ Analysis of Mutant EGFRs Prevalent in Glioblastoma Multiforme Reveals Aberrant Dimerization, Activation, and Differential Response to Anti-EGFR Targeted Therapy. Mol. Cancer. Res. 2012 ; 10: 428-440
21. Pines G., Kostler W. J., Yarden Y.. Oncogenic Mutant Forms of EGFR: Lessons in Signal Transduction and Targets for Cancer Therapy. FEBS Lett. 2010 ; 584: 2699-2706
22. Musolino A., Naldi N., Bortesi B., et al. Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients with HER/neu-Positive Metastatic Breast Cancer. J. Clin. Oncol. 2008 ; 26: 1789-1796
23. Niwa R., Natsume A., Uehara A., et al. IgG Subclass-Independent Improvement of Antibody-Dependent Cellular Cytotoxicity by Fucose Removal from Asn297-Linked Oligosaccharides. J. Immunol. Methods. 2005 ; 306: 151-160
24. Beck A., Reichert J. M.. Marketing Approval of Mogamuli-zumab: A Triumph for Glyco-Engineering. mAbs. 2012 ; 4: 419-425
25. Holliger P., Hudson P. J.. Engineered Antibody Fragments and the Rise of Single Domains. Nat. Biotechnol. 2005 ; 23: 1126-1136
26. Saerens D., Ghassabeh G. H., Muyldermans S.. Single-Domain Antibodies as Building Blocks for Novel Therapeutics. Curr. Opin. Pharmacol. 2008 ; 8: 600-608
27. Muyldermans S.. Nanobodies: Natural Single-Domain Antibodies. Annu. Rev. Biochem. 2013 ; 82: 775-797
28. Ulrichts H., Silence K., Schoolmeester A., et al. Antithrinbotic Drug Candidate ALX-0081 Shows Superior Preclinical Efficacy and Safety Compared with Currently Marketed Antiplatelet Drugs. Blood. 2011 ; 118: 757-765
29. Vanlandschoot P., Stortelers C., Beirnaert E., et al. Nanobodies: New Ammunition to Battle Viruses. Antiviral Res. 2011 ; 92: 389-407
30. Wu A. W.. Engineered Antibodies for Molecular Imaging of Cancer. Methods. 2014 ; 65: 139-147
31. Constantinou A., Chen C., Deonarain M. P.. Modulating the Pharmacokinetics of Therapeutic Antibodies. Biotechnol. Lett. 2010 ; 32: 609-622
32. Nelson A. L., Reichert J. M.. Development Trends for Therapeutic Antibody Fragments. Nat. Biotechnol. 2009 ; 27: 331-337
33. Holliger P., Prospero T., Winter G.. Diabodies: Small Bivalent and Bispecific Antibody Fragments. Proc. Natl. Acad. Sci. U. S. A. 1993 ; 90: 6444-6448
34. Hudson P. J., Kortt A. A.. High Avidity scFv Multimers; Diabodies and Tribodies. J. Immunol. Methods. 1999 ; 231: 177-189
35. Todorovska A., Roovers R. C., Dolezal O., et al. Design and Application of Diabodies, Triabodies and Tetrabodies for Cancer Targeting. J. Immunol. Methods. 2001 ; 248: 47-66
36. Dimasi N., Gao C., Fleming R., et al. The Design and Characterisation of Oligospecific Antibodies for Simultaneous Targeting of Multiple Disease Mediators. J. Mol. Biol. 2009 ; 393: 672-692
37. Byrne H., Conroy P. J., Whisstock J. C., et al. A Tale of Two Specificities: Bispecific Antibodies for Therapeutic and Diagnostic Applications. Trends Biotechnol. 2013 ; 31: 621-632
38. Weidle U. H., Tiefenthaler G., Weiss E. H., et al. The Intriguing Options of Multispecific Antibody Formats for Treatment of Cancer. Cancer Genom. Proteom. 2013 ; 10: 1-18
39. Shatz W., Chung S., Li B., et al. Knobs-into-Holes Antibody Production in Mammalian Cell Lines Reveals That Asymmetric Afucosylation Is Sufficient for Full Antibody-Dependent Cellular Cytotoxicity. mAbs. 2013 ; 5: 872-881
40. Elliott J. M., Ultsch M., Lee J., et al. Antiparallel Conformation of Knob and Hole Aglycosylated Half-Antibody Homodimers Is Mediated by a CH2-CH3 Hydrophobic Interaction. J. Mol. Biol. 2014 ; 426: 1947-1957
41. Dong J., Sereno A., Snyder W. B., et al. Stable IgG-Like Bispecific Antibodies Directed toward the Type I Insulin-Like Growth Factor Receptor Demonstrate Enhanced Ligand Blockade and Anti-Tumor Activity. J. Biol. Chem. 2011 ; 286: 4703-4717
42. Schanzer J. M., Wartha K., Croasdale R., et al. A Novel Glycoengineered Bispecific Antibody Format for Targeted Inhibition of EGFR and IGF-1R Demonstrating Unique Molecular Properties. J. Biol. Chem. 2014 ; 289: 18639-18706
43. Frankel S. R., Baeuerle P. A.. Targeting T Cells to Tumor Cells Using Bispecific Antibodies. Curr. Opin. Chem. Biol. 2013 ; 17: 385-392
44. Rossi D. L., Rossi E. A., Cardillo T. M., et al. A New Class of Bispecific Antibodies to Redirect T Cells for Cancer Immunotherapy. mAbs. 2014 ; 6: 381-391
45. Watts R. J., Dennis M. S.. Bispecific Antibodies for Delivery into the Brain. Curr. Opin. Chem. Biol. 2013 ; 17: 1-7
46. Maher J., Adami A. A.. Antitumor Immunity: Easy as 1, 2, 3 with Monoclonal Bispecific Trifunctional Antibodies?. Cancer Res. 2013 ; 73: 5613-5617
47. Carter P. J., Senter P. D.. Antibody-Drug Conjugates for Cancer Therapy. Cancer J. 2008 ; 14: 154-169
48. Mullard A.. Maturing Antibody-Drug Conjugate Pipeline Hits 30. Nat. Rev. Drug Discov. 2013 ; 12: 329-332
49. Beck A., Reichert J. M.. Antibody-Drug Conjugates: Present and Future. mAbs. 2014 ; 6: 15-17
50. Ricart A. D., Tolcher A. W.. Technology Insight: Cytotoxic Drug Immunoconjugates for Cancer Therapy. Nat. Clin. Pract. 2007 ; 4: 235-255
51. Chari R. V. J.. Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs. Accounts Chem. Res. 2008 ; 41: 98-107
52. Panowski S., Bhakta S., Raab H., et al. Site-Specific Antibody Drug Conjugates for Cancer Therapy. mAbs. 2014 ; 6: 34-45
53. Roberts S. A., Andrews P. A., Blanset D., et al. Considerations for the Nonclinical Safety Evaluation of Antibody Drug Conjugates for Oncology. Regul. Toxicol. Pharmacol. 2013 ; 67: 382-391
54. Behrens C. R., Liu B.. Methods for Site-Specific Drug Conjugation to Antibodies. mAbs. 2014 ; 6: 46-53
55. Polson A. G., Calemine-Fenaux J., Chan P., et al. Antibody-Drug Conjugates for the Treatment of Non-Hodgkin's Lymphoma: Target and Linker-Drug Selection. Cancer Res. 2009 ; 69: 2358-2364
56. Shen B.-Q., Xu K., Liu L., et al. Conjugation Site Modulates the In Vivo Stability and Therapeutic Activity of Antibody-Drug Conjugates. Nat. Biotechnol. 2012 ; 30: 184-189
57. Junutula J. R., Raab H., Clark S., et al. Site-Specific Conjugation of a Cytotoxic Drug to an Antibody Improves the Therapeutic Index. Nat. Biotechnol. 2008 ; 26: 925-932
58. Tian F., Lu Y., Manibusan A., et al. A General Approach to Site-Specific Antibody-Drug Conjugates. Proc. Natl. Acad. Sci. U. S. A. 2014 ; 111: 1766-1771
59. Jackson D., Atkinson J., Guevara C. I., et al. In Vitro and In Vivo Evaluation of Cysteine and Site Specific Conjugated Herceptin Antibody-Drug Conjugates. PLoS One. 2014 ; 9 :
60. Pasche N., Neri D.. Immunocytokines: A Novel Class of Potent Armed Antibodies. Drug Discov. Today. 2012 ; 17: 583-590
61. Yang X., Zhang X., Fu M. L., et al. Targeting the Tumour Microenvironment with Interferon-β Bridges Innate and Adaptive Immune Responses. Cancer Cell. 2014 ; 25: 37-48
62. Schrama D., Reisfeld R. A., Becker J. C.. Antibody Targeted Drugs as Cancer Therapeutics. Nat. Rev. Drug Discov. 2006 ; 5: 147-159
63. Govindan S. V., Goldenberg D. M.. Designing Immuno-conjugates for Cancer Therapy. Expert Opin. Biol. Ther. 2012 ; 12: 873-890
64. Ma H., Meng J., Wang J., et al. Targeted Delivery of a SNARE Protease to Sensory Neurons Using a Single Chain Antibody (scFv) against the Extracellular Domain of P2X3 Inhibits the Release of a Pain Modulator. Biochem. J. 2014 ; 462: 247-256
65. Desnoyers L. R., Vasiljeva O., Richardson J. H., et al. Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index. Sci. Transl. Med. 2013 ; 5 :
66. Kirpotin D. B., Noble C. O., Hayes M. E., et al. Building and Characterising Antibody-Targeted Lipidic Nanotherapeutics. Methods Enzymol. 2012 ; 502: 139-166
67. Nielsen U. B., Kirpotin D. B., Pickering E. M., et al. Therapeutic Efficacy of Anti-Erb2 Immunoliposomes Targeted by a Phage Antibody Selected for Cellular Endocytosis. Biochim. Biophys. Acta. 2002 ; 1591: 109-118
68. Blazer L. L., Neubig R. R.. Small Molecule Protein-Protein Interaction Inhibitors as CNS Therapeutic Agents: Current Progress and Future Hurdles. Neuropsychopharmacology. 2009 ; 34: 126-141
69. Ivanov A. A., Khuri F. R., Fu H.. Targeting Protein-Protein Interactions as an Anticancer Strategy. TIPS. 2013 ; 34: 393-400
70. Arkin M. R., Wells J. A.. Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing towards the Dream. Nat. Rev. Drug Discov. 2004 ; 3: 301-317
71. DeLano W. L., Ultsch M. H., de Vos A. M., et al. Convergent Solutions to Binding at a Protein-Protein Interface. Science. 2000 ; 287: 1279-1283
72. Bonacci T. M., Matthews J. L., Yuan C., et al. Differential Targeting of Gbetagamma-Subunit Signalling with Small Molecules. Science. 2006 ; 312: 443-446
73. Temsamani J, Vidal P.. The Use of Cell-Penetrating Peptides for Drug Delivery. Drug Discov. Today. 2004 ; 9: 1012-1019
74. Murriel C. L., Dowdy S. F.. Influence of Protein Transduction Domains on Intracellular Delivery of Macromolecules. Expert Opin. Drug Deliv. 2006 ; 3: 739-746
75. Haas A. K., Maisel D., Adelmann J., et al. Human-Protein-Derived Peptides for Intracellular Delivery of Biomolecules. Biochem. J. 2012 ; 442: 583-593
76. Varkouhi A. K., Scholte M., Storm G., et al. Endosomal Escape Pathways for Delivery of Biologicals. J. Controlled Rel. 2011 ; 151: 220-228
77. Covic L., Gresser A. L., Talavera J., et al. Activation and Inhibition of G Protein-Coupled Receptors by Cell-Penetrating Membrane-Tethered Peptides. Proc. Natl. Acad. Sci. U. S. A. 2002 ; 99: 643-648
78. O'Callaghan K., Kuliopulos A., Covic L.. Turning Receptors on and off with Intracellular Pepducins: New Insights into G-Protein-Coupled Receptor Drug Development. J. Biol. Chem. 2012 ; 287: 12787-12796
79. Carlson K. E., McMurry T. J., Hunt S. W.. Pepducins: Lipopeptide Allosteric Modulators of GPCR Signaling. Drug Discov. Today Technol. 2012 ; 9: e33 - e39
80. Okamoto T., Zobel K., Fedorova A., et al. Stabilizing the Pro-Apoptotic BimBH3 Helix (BimSAHB) Does Not Necessarily Enhance Affinity or Biological Activity. ACS Chem. Biol. 2013 ; 8: 297-302
81. McNaughton B. R., Cronican J. J., Thompson D. B., et al. Mammalian Cell Penetration, siRNA Transfection and DNA Transfection by Supercharged Proteins. Proc. Natl. Acad. Sci. U. S. A. 2009 ; 106: 6111-6116
82. Kaiser P. D., Maier J., Traenkle B., et al. Recent Progress in Generating Intracellular Functional Antibody Fragments to Target and Trace Cellular Components in Living Cells. Biochim. Biophys. Acta. 2014 ; 1844: 1933-1942
83. Hansen J. E., Chan G., Liu Y., et al. Targeting Cancer with a Lupus Autoantibody. Sci. Transl. Med. 2012 ; 4 :
84. Weisbart R. H., Baldwin R., Huh B., et al. Novel Protein Transfection of Primary Rat Cortical Neurons Using an Antibody That Penetrates Living Cells. J. Immunol. 2000 ; 164: 6020-6026
85. Tanaka T., Lobato M. N., Rabbitts T. H.. Single Domain Intracellular Antibodies: A Minimal Fragment for Direct In Vivo Selection of Antigen-Specific Intrabodies. J. Mol. Biol. 2003 ; 331: 1109-1120
86. Zhang J., Rabbitts T. H.. Intracellular Antibody Capture: A Molecular Biology Approach to Inhibitors of Protein-Protein Interactions. Biochim. Biophys. Acta. 2014 ; 1844: 1970-1976
87. Visintin M., Melchionna T., Cannistraci I., et al. In Vivo Selection of Intrabodies Specifically Targeting Protein-Protein Interactions: A General Platform for an "Undruggable" Class of Disease Targets. J. Biotechnol. 2008 ; 135: 1-15
88. Hutchings C. J., Koglin M., Marshall F. H.. Therapeutic Antibodies Directed at G Protein-Coupled Receptors. mAbs. 2010 ; 2: 594-606
89. Webb D. R., Handel T. M., Kretz-Rommel A., et al. Opportunities for Functional Selectivity in GPCR Antibodies. Biochem. Pharmacol. 2013 ; 85: 147-152
90. Liu B., Conrad F., Cooperberg M. R., et al. Mapping Tumor Epitope Space by Direct Selection of Single-Chain Fv Libraries on Prostate Cancer Cells. Cancer Res. 2004 ; 64: 704-710
91. Schwarz M., Rottgen P., Takada Y., et al. Single-Chain Antibodies for the Conformation-Specific Blockade of Activated Platelet Integrin alphaIIbbeta3 Designed by Subtractive Selection from Naïve Human Phage Libraries. FASEB J. 2004 ; 18: 1704-1706
92. van der Horst E. H., Chinn L., Wang M., et al. Discovery of Fully Human Anti-MET Monoclonal Antibodies with Antitumor Activity against Colon Cancer Tumor Models In Vivo. Neoplasia. 2009 ; 11: 355-364
93. Wang C. A., Lewis R. J.. Emerging Opportunities for Allosteric Modulation of G-Protein Coupled Receptors. Biochem. Pharmacol. 2013 ; 85: 153-162
94. Monaghan D. T., Irvine M. W., Costa B. M., et al. Pharmacological Modulation of NMDA Receptor Activity and the Advent of Negative and Positive Allosteric Modulators. Neurochem. Int. 2012 ; 61: 581-592
95. Burford N. T., Watson J., Bertekap R., et al. Strategies for the Identification of Allosteric Modulators of G-Protein-Coupled Receptors. Biochem. Pharmacol. 2011 ; 81: 691-702
96. Kenakin T. P.. Ligand Detection in the Allosteric World. J. Biomol. Screen. 2010 ; 15: 119-130
97. Eglen R. M., Bosse R., Reisine T.. Emerging Concepts of Guanine Nucleotide-Binding Protein-Coupled Receptor (GPCR) Function and Implications for High Throughput Screening. Assay Drug Dev. Technol. 2007 ; 5: 425-451
98. Wu L., Ruffing N., Shi X., et al. Discrete Steps in Binding and Signalling of Interleukin-8 with Its Receptor. J. Biol. Chem. 1996 ; 271: 31202-31209
99. Sieghart W.. Structure and Pharmacology of γ-Aminobutyric AcidA Receptor Subtypes. Pharmacol. Rev. 1995 ; 47: 181-234
100. Issafras H., Bedinger D. H., Corbin J. A., et al. Selective Allosteric Antibodies to the Insulin Receptor for the Treatment of Hyperglycemic and Hypoglycemic Disorders. J. Diabetes Sci. Technol.. :
101. Ullmer C., Zoffmann S., Bohrmann B., et al. Functional Monoclonal Antibody Acts as a Biased Agonist by Inducing Internalization of Metabotropic Glutamate Receptor 7. Br. J. Pharmacol. 2012 ; 167: 1448-1466
102. Mukund S., Shang Y., Clarke H. J., et al. Inhibitory Mechanism of an Allosteric Antibody Targeting the Glucagon Receptor. J. Biol. Chem. 2013 ; 288: 36168-36178
103. Hino T., Arakawa T., Iwanari H., et al. G-Protein-Coupled Receptor Inactivation by an Allosteric Inverse-Agonist Antibody. Nature. 2012 ; 482: 237-240
104. Doern A., Cao X., Sereno A., et al. Characterization of Inhibitory Anti-Insulin-Like Growth Factor Receptor Antibodies with Different Epitope Specificity and Ligand-Blocking Properties: Implications for Mechanisms of Action In Vivo. J. Biol. Chem. 2009 ; 284: 10254-10267
105. Cazorla M., Arrang J. M., Premont J.. Pharmacological Characterization of Six trkB Antibodies Reveals a Novel Class of Functional Agents for the Study of the BDNF Receptor. Br. J. Pharmacol. 2011 ; 162: 947-960
106. Wang W., Liu Y., Lazarus R. A.. Allosteric Inhibition of BACE1 by an Exosite-Binding Antibody. Curr. Opin. Struct. Biol. 2013 ; 23: 797-805
107. Mahalingam B., Van Agthoven J. F., Xiong J. P., et al. Atomic Basis for the Species-Specific Inhibition of αV Integrins by mAb 17E6 Is Revealed by the Crystal Structure of αVβ3 Ectodomain-17E6 Fab Complex. J. Biol. Chem. 2014 ; 289: 13801-13809
108. Bond R. A., Ijzerman A. P.. Recent Developments in Constitutive Receptor Activity and Inverse Agonism, and Their Potential for GPCR Drug Discovery. TIPS. 2006 ; 27: 92-96
109. Hutchings C. J., Cseke G., Osborne G., et al. Monoclonal Anti-β1-Adrenergic Receptor Antibodies Activate G Protein Signalling in the Absence of β-Arrestin Recruitment. mAbs. 2014 ; 6: 246-261
110. Sanders J., Miguel R. N., Furmaniak J., et al. TSH Receptor Monoclonal Antibodies with Agonist, Antagonist and Inverse Agonist Activities. Methods Enzymol. 2010 ; 485: 393-420
111. Peter J.-C., Eftekhari P., Billiald P., et al. scFv Single Chain Antibody Variable Fragment as Inverse Agonist of the β2-Adrenergic Receptor. J. Biol. Chem. 2003 ; 278: 36740-36747
112. Peter J.-C., Wallukat G., Tugler J., et al. Modulation of the M2 Muscarinic Acetylcholine Receptor Activity with Monoclonal Anti-M2 Receptor Antibody Fragments. J. Biol. Chem. 2004 ; 279: 55697-55706
113. Chen C.-R., McLachlan S. M., Rapoport B.. Identification of Key Amino Acid Residues in a Thyrotropin Receptor Monoclonal Antibody Epitope Provides Insight into Its Inverse Agonist and Antagonist Properties. Endocrinology. 2008 ; 149: 3427-3434
114. Koth C. M., Murray J. M., Mukund S., et al. Molecular Basis for Negative Regulation of the Glucagon Receptor. Proc. Natl. Acad. Sci. U. S. A. 2012 ; 109: 14393-14398
115. Kenakin T. P.. Functional Selectivity through Protean and Biased Agonism: Who Steers the Ship?. Mol. Pharmacol. 2007 ; 72: 1393-1401
116. Rajagopal S., Rajagopal K., Lefkowitz R. J.. Teaching Old Receptors New Tricks: Biasing Seven-Transmembrane Receptors. Nat. Rev. Drug Discov. 2010 ; 9: 373-386
117. Gupta A., Decaillot F. M., Gomes I., et al. Conformation State-Sensitive Antibodies to G-Protein-Coupled Receptors. J. Biol. Chem. 2007 ; 282: 5116-5124
118. Staus D. P., Wingler L. M., Strachan R. T., et al. Regulation of β2-Adrenergic Receptor Function by Conformationally Selective Single-Domain Intrabodies. Mol. Pharmacol. 2013 ; 85: 472-481
119. Grütter C., Wilkinson T., Turner R., et al. A Cytokine-Neutralizing Antibody as a Structural Mimetic of 2 Receptor Interactions. Proc. Natl. Acad. Sci. USA. 2008 ; 105: 20251-20256
120. Machold K. P., Smolen J. S.. Adalimumab - A New TNF-alpha Antibody for Treatment of Inflammatory Joint Disease. Expert Opin. Biol. Ther. 2003 ; 3: 351-360
121. Melero I, Hervas-Stubbs S., Glennie M., et al. Immunostimulatory Monoclonal Antibodies for Cancer Therapy. Nat. Rev. Cancer. 2007 ; 7: 95-106
122. Vonderheide R. H., Glennie M. J.. Agonistic CD40 Antibodies and Cancer Therapy. Clin. Cancer Res. 2013 ; 19: 1035-1043
123. Chodorge M., Zuger S., Stirnimann C., et al. A Series of Fas Receptor Agonist Antibodies That Demonstrate an Inverse Correlation between Affinity and Potency. Cell Death Different. 2012 ; 19: 1187-1195
124. Panetta R., Greenwood M. T.. Physiological Relevance of GPCR Oligomerization and Its Impact on Drug Discovery. Drug Discov. Today. 2008 ; 13: 1059-1066
125. Fauvel B., Yasri A.. Antibodies Directed against Receptor Tyrosine Kinases: Current and Future Strategies to Fight Cancer. mAbs. 2014 ; 6: 1-14
126. Tombola F., Pathak M. M., Isacoff E. Y.. How Does Voltage Open an Ion Channel?. Annu. Rev. Cell Dev. Biol. 2006 ; 22: 23-52
127. Vardanyan V., Pongs O.. Coupling of Voltage-Sensors to the Channel Pore: A Comparative View. Frontiers Pharmacol. 2012 ; 3 :
128. Lu Q., An W. F.. Impact of Novel Screening Technologies on Ion Channel Drug Discovery. Comb. Chem. High Throughput Screen. 2008 ; 11: 185-194
129. Dallas M. L., Deuchars S. A., Deuchars J.. Immuno-pharmacology: Utilizing Antibodies as Ion Channel Modulators. Expert Rev. Clin. Pharmacol. 2010 ; 3: 281-289
130. Sun H., Li M.. Antibody Therapeutics Targeting Ion Channels: Are We There Yet?. Acta Pharmacologica Sinica. 2013 ; 34: 199-204
131. Chioni A.-M., Fraser S. P., Pani F., et al. A Novel Polyclonal Antibody Specific for the Nav 1.5 Voltage-Gated Na+ Channel 'Neonatal' Splice Form. J. Neurosci. Methods. 2005 ; 147: 88-98
132. Lang B., Vincent A.. Autoantibodies to Ion Channels at the Neuromuscular Junction. Autoimmun. Rev. 2003 ; 2: 94-100
133. Flink M. T., Atchison W. D.. Ca2+ Channels as Targets of Neurological Disease: Lambert-Eaton Syndrome and Other Ca2+ Channelopathies. J. Bioenerg. Biomembr. 2003 ; 35: 697-718
134. Wyatt C. N., Campbell V., Brodbeck J., et al. Voltage-Dependent Binding and Calcium Channel Current Inhibition by an Anti-α1D Subunit Antibody in Rat Dorsal Root Ganglion Neurones and Guinea-Pig Myocytes. J. Physiol. 1997 ; 502: 307-319
135. Mirzabekov T., Kontos H., Farzan M., et al. Paramagnetic Proteoliposomes Containing a Pure, Native, and Oriented Seven-Transmembrane Segment Protein, CCR5. Nat. Biotechnol. 2000 ; 18: 649-654
136. Hedfalk K.. Further Advances in the Production of Membrane Proteins in Pichia pastoris. Bioengineered. 2013 ; 4: 363-367
137. Naylor J., Beech D. J.. Extracellular Ion Channel Inhibitor Antibodies. Open Drug Discov. J. 2009 ; 1: 36-42
138. Xu S. Z., Zeng F., Lei M., et al. Generation of Functional Ion-Channel Tools by E3 Targeting. Nat. Biotechnol. 2005 ; 23: 1289-1293
139. Yang X.-F., Yang Y., Lian Y.-T., et al. The Antibody Targeting the E314 Peptide of Human Kv1.3 Pore Region Serves as a Novel, Potent and Specific Channel Blocker. PLoS One. 2012 ; 7: e36379
140. Klionsky L., Tamir R., Holzinger B., et al. A Polyclonal Antibody to the Pre-Pore Loop of TRPV1 Blocks Channel Activation. J. Pharmacol. Exp. Ther. 2006 ; 319: 192-198
141. Gomez-Varela D., Zwick-Wallasch E., Knotgen H., et al. Monoclonal Antibody Blockade of the Human Eag1 Potassium Channel Function Exerts Antitumour Activity. Cancer Res. 2007 ; 67: 7343-7349
142. Lee J.-H., Park C.-K., Chen G., et al. A Monoclonal Antibody That Targets a Nav 1.7 Channel Voltage Sensor for Pain and Itch Relief. Cell. 2014 ; 157: 1393-1404
143. Buell G., Chessell I. P., Michel A. D., et al. Blockade of Human P2X7 Receptor Function with a Monoclonal Antibody. Blood. 1998 ; 10: 3521-3528
144. Lee K. J., Wang W., Padaki R., et al. Mouse Monoclonal Antibodies to Transient Receptor Potential Ankyrin 1 Act as Antagonists of Multiple Modes of Channel Activation. J. Pharmacol. Exp. Ther. 2014 ; 350: 223-231
145. Frank R. T., Aboody K. S., Najbauer J.. Strategies for Enhancing Antibody Delivery to the Brain. Biochim. Biophys. Acta. 2011 ; 1816: 191-198
146. Scherrmann J.-M.. Drug Delivery to Brain via the Blood-Brain Barrier. Vasc. Pharmacol. 2002 ; 38: 349-354
147. Abbott N. J., Patabendige A. A. K., Dolman D. E. M., et al. Structure and Function of the Blood-Brain Barrier. Neurobiol. Dis. 2010 ; 37: 13-25
148. Pardridge W. M.. Blood-Brain Barrier Delivery. Drug Discov. Today. 2007 ; 12: 54-61
149. De Rosa G., Salzano G., Caraglia M., et al. Nanotechnologies: A Strategy to Overcome Blood-Brain Barrier. Curr. Drug. Metab. 2012 ; 13: 61-69
150. Gaillard P. J., Appeldoorn C. C. M., Dorland R., et al. Pharmacokinetics, Brain Delivery, and Efficacy in Brain Tumor-Bearing Mice of Glutathione Pegylated Liposomal Doxorubicin (2B2-101). PLoS One. 2014 ; 9: e82331
151. Gao X., Wu B., Zhang Q., et al. Brain Delivery of Vasoactive Intestinal Peptide Enhanced with the Nanoparticles Conjugated with Wheat Germ Agglutinin following Intranasal Administration. J. Control. Rel. 2007 ; 121: 156-167
152. Muruganandam A., Tanha J., Narang S., et al. Selection of Phage-Displayed Llama Single-Domain Antibodies That Transmigrate across the Human Blood-Brain Barrier Endothelium. FASEB J. 2002 ; 16: 240-242
153. Abulrob A. A., Sprong H., Van Bergen en, Henegouwen P., et al. The Blood-Brain Barrier Transmigrating Single Domain Antibody: Mechanisms of Transport and Antigenic Epitopes in Human Brain Endothelial Cells. J. Neurochem. 2005 ; 95: 1201-1214
154. Song B.-W., Vinters H. V., Wu D., et al. Enhanced Neuroprotective Effects of Basic Fibroblast Growth Factor in Regional Brain Ischemia after Conjugation to a Blood-Brain Delivery Vector. J. Pharmacol. Exp. Ther. 2002 ; 301: 605-610
155. Penichet M. L., Kang Y.-S., Pardridge W. M., et al. An Antibody-Avidin Fusion Protein Specific for the Transferrin Receptor Serves as a Delivery Vehicle for Effective Brain Targeting: Initial Applications in Anti-HIV Antisense Delivery to the Brain. J. Immunol. 1999 ; 163: 4421-4426
156. Cooper P. R., Ciambrone G. J., Kliwinski C. M., et al. Efflux of Monoclonal Antibodies from Rat Brain by Neonatal Fc Receptor, FcRn. Brain Res. 2013 ; 1534: 13-21
157. Boado R. J., Zhang Y., Zhang Y., et al. Fusion Antibody for Alzheimer's Disease with Bi-Directional Transport across the Blood-Brain Barrier and Abeta Fibril Disaggregation. Bioconjug. Chem. 2007 ; 18: 447-455
158. Yu Y. J., Zhang Y., Kenrick M., et al. Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target. Sci. Translat. Med. 2011 ; 3: 1-8
159. Wunder F., Kalthof B., Muller T., et al. Functional Cell-Based Assays in Microliter Volumes for Ultra-High Throughput Screening. Comb. Chem. High Throughput Screen. 2008 ; 11: 495-504
160. Mayr L. M., Bojanic D.. Novel Trends in High-Throughput Screening. Curr. Opin. Pharmacol. 2009 ; 9: 580-588
161. Michelini E., Cevenini L., Mezzanotte L., et al. Cell-Based Assays: Fuelling Drug Discovery. Anal. Bioanal. Chem. 2010 ; 398: 227-238
162. Kohler G., Milstein C.. Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity. Nature. 1975 ; 256: 495-497
163. Kipriyanov S. M., Moldenhauer G., Little M.. High Level Production of Soluble Single Chain Antibodies in Small-Scale Escherichia coli Cultures. J. Immunol. Methods. 1997 ; 200: 69-77
164. Bradbury A. R. M., Marks J. D.. Antibodies from Phage Antibody Libraries. J. Immunol. Methods. 2004 ; 290: 29-49
165. Scott N., Reynolds C. B., Wright M. J., et al. Single-Chain Fv Phage Display Propensity Exhibits Strong Positive Correlation with Overall Expression Levels. BMC Biotechnol. 2008 ; 8: 97-107
166. Smith A. J., Hancock M. K., Bi K., et al. Feasibility of Implementing Cell-Based Pathway Reporter Assays in Early High-Throughput Screening Assay Cascades for Antibody Drug Discovery. J. Biomol. Screen. 2012 ; 17: 713-726
167. Smith A. J., Simpson P. B.. Methodological Approaches for the Study of GABAA Receptor Pharmacology and Functional Responses. Anal. Bioanal. Chem. 2003 ; 377: 843-851
168. Doerner A., Rhiel L., Zielonka S., et al. Therapeutic Antibody Engineering by High Efficiency Cell Screening. FEBS Lett. 2014 ; 588: 278-287
169. Shaheen H. H., Prinz B., Chen M. T., et al. A Dual-Mode Surface Display System for the Maturation and Production of Monoclonal Antibodies in Glyco-Engineered. Pichia pastoris. PLoS One. 2013 ; 8: e70190
170. Araya C. L., Fowler D. M.. Deep Mutational Scanning: Assessing Protein Function on a Massive Scale. Trends Biotechnol. 2011 ; 29: 435-442
171. Ravn U., Didelot G., Venet S., et al. Deep Sequencing of Phage Display Libraries to Support Antibody Discovery. Methods. 2013 ; 60: 99-110
172. D'Angelo S., Glanville J., Ferrara F., et al. The Antibody Mining Toolbox. mAbs. 2014 ; 6: 160-172
173. Melidoni A. N., Dyson M. R., Wormald S., et al. Selecting Antagonistic Antibodies That Control Differentiation through Inducible Expression in Embryonic Stem Cells. Proc. Natl. Acad. Sci. U. S. A. 2013 ; 110: 17802-17807
174. Zhang H., Yea K., Xie J., et al. Selecting Agonists from Single Cells Infected with Combinatorial Antibody Libraries. Chem. Biol. 2013 ; 20: 734-741
175. Yea K., Zhang H., Xie J., et al. Converting Stem Cells to Dendritic Cells by Agonist Antibodies from Unbiased Morphogenic Selections. Proc. Natl. Acad. Sci. U. S. A. 2013 ; 110: 14966-14971
176. Eglen R., Reisine T.. Primary Cells and Stem Cells in Drug Discovery: Emerging Tools for High-Throughput Screening. Assay Drug Develop. Technol. 2011 ; 9: 108-124
177. LaBarbera D. V., Reid B. G., Yoo B. H.. The Multicellular Tumor Spheroid Model for High-Throughput Cancer Drug Discovery. Expert Opin. Drug Discov. 2012 ; 7: 819-830
178. Mouchet E. H., Simpson P. B.. High-Content Assays in Oncology Drug Discovery: Opportunities and Challenges. IDrugs. 2008 ; 11: 422-427
179. Zanella F., Lorens J. B., Link W.. High Content Screening: Seeing Is Believing. Trends Biotechnol. 2010 ; 28: 237-245
180. Bickle M.. The Beautiful Cell: High-Content Screening in Drug Discovery. Anal. Bioanal. Chem. 2010 ; 398: 219-226
181. Singh S., Carpenter A. E., Genovesio A.. Increasing the Content of High-Content Screening: An Overview. J. Biomol. Screen. 2014 ; 19: 640-650
182. Bornot A., Blackett C., Engkvist O., et al. The Role of Historical Bioactivity Data in the Deconvolution of Phenotypic Screens. J. Biomol. Screen. 2014 ; 19: 696-706
183. Rust S., Guillard S., Sachsenmeier K., et al. Combining Phenotypic and Proteomic Approaches to Identify Membrane Targets in a 'Triple Negative' Breast Cancer Cell Type. Mol. Cancer. 2013 ; 12: 11
184. DiGiandomenico A., Warrener P., Hamilton M., et al. Identification of Broadly Protective Human Antibodies to Pseudomonas aeruginosa Exopolysaccharide Psl by Phenotypic Screening. J. Exp. Med. 2012 ; 209: 1273-1287
185. Katritch V., Cherezov V., Stevens R. C.. Structure-Function of the G Protein-Coupled Receptor Superfamily. Ann. Rev. Pharmacol. Toxicol. 2013 ; 53: 531-556
186. Yu F. H., Yarov-Yarovoy V., Gutman G. A., et al. Overview of Molecular Relationships in the Voltage-Gated Ion Channel Superfamily. Pharmacol. Rev. 2005 ; 57: 387-395
187. Catterall W. A.. Structure and Function of Voltage-Gated Ion Channels. Ann. Rev. Biochem. 1995 ; 64: 493-531